Mark W. Duncan

Mark W. Duncan, Ph.D., Chief Scientific Officer, has extensive experience in mass spectrometry, clinical diagnostics and analytical chemistry. Dr. Duncan holds B.Sc. (Hons) and Ph.D. degrees from the University of New South Wales. He was a Postgraduate Scholar at the Garvan Institute of Medical Research, Sydney, Australia and a Fogerty Fellow at the National Institute of Neurological Disorders & Stroke, National Institutes of Health (NIH), Bethesda, MD. He has held appointments as a Professor (Medicine) at Universities in Australia, the USA and Saudi Arabia and has established and directed MS resources at three international institutions. He has also held senior executive positions in industry and is a co-developer of Veristrat®, a blood-based diagnostic used in the management of patients with non-small cell lung cancer, marketed by Biodesix, Inc., Boulder, Colorado. He has published over 150 publications and has 8 issued patents. Dr. Duncan is co-editor, Special Features, Journal of Mass Spectrometry, he is on the editorial board, Journal of Clinical Mass Spectrometry and he is a member of the Committee on Quantitative Measurement of Proteins & Peptides by MS (C64), Clinical & Laboratory Standards Institute.